160 related articles for article (PubMed ID: 28983992)
21. An update on the first decade of the European centralized procedure: how many innovative drugs?
Motola D; De Ponti F; Poluzzi E; Martini N; Rossi P; Silvani MC; Vaccheri A; Montanaro N
Br J Clin Pharmacol; 2006 Nov; 62(5):610-6. PubMed ID: 16796703
[TBL] [Abstract][Full Text] [Related]
22. Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015.
Grössmann N; Robausch M; Rosian K; Wild C; Simon J
Eur J Cancer; 2019 Mar; 110():1-7. PubMed ID: 30735832
[TBL] [Abstract][Full Text] [Related]
23. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
Hwang TJ; Tomasi PA; Bourgeois FT
PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
[TBL] [Abstract][Full Text] [Related]
24. Efficacy, safety and cost of new cardiovascular drugs: a survey.
Garattini S; Bertele' V
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):701-6. PubMed ID: 12961050
[TBL] [Abstract][Full Text] [Related]
25. [Hope for patients with rare diseases--"orphan" drugs].
Kuzelová M; Kubácková K; Palágyi M; Smíd M
Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
[TBL] [Abstract][Full Text] [Related]
26. Imposed registries within the European postmarketing surveillance system: Extended analysis and lessons learned for regulators.
Pacurariu A; Plueschke K; Olmo CA; Kurz X
Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):823-826. PubMed ID: 29749086
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non-orphan, Non-oncology Drugs in the European Union and United States from 2012-2016.
Morant AV; Jagalski V; Vestergaard HT
Clin Transl Sci; 2019 Jul; 12(4):361-370. PubMed ID: 30681284
[TBL] [Abstract][Full Text] [Related]
28. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2014.
Deane BR; Porkess S
Curr Med Res Opin; 2018 Jul; 34(7):1239-1243. PubMed ID: 29219621
[TBL] [Abstract][Full Text] [Related]
29. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
30. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
[TBL] [Abstract][Full Text] [Related]
31. A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.
Zeukeng MJ; Seoane-Vazquez E; Bonnabry P
Eur J Clin Pharmacol; 2018 Jun; 74(6):811-818. PubMed ID: 29470610
[TBL] [Abstract][Full Text] [Related]
32. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
Enzmann H; Broich K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
[TBL] [Abstract][Full Text] [Related]
33. Investigating the landscape of US orphan product approvals.
Miller KL; Lanthier M
Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
[TBL] [Abstract][Full Text] [Related]
34. The lag from FDA approval to published cost-utility evidence.
Chambers JD; Thorat T; Pyo J; Neumann PJ
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):399-402. PubMed ID: 25579324
[TBL] [Abstract][Full Text] [Related]
35. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
Borg JJ; Robert JL; Wade G; Aislaitner G; Pirozynski M; Abadie E; Salmonson T; Vella Bonanno P
J Pharm Pharm Sci; 2009; 12(2):181-98. PubMed ID: 19732496
[TBL] [Abstract][Full Text] [Related]
36. Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology.
Pignatti F; Aronsson B; Vamvakas S; Wade G; Papadouli I; Papaluca M; Moulon I; Le Courtois P
Crit Rev Oncol Hematol; 2002 May; 42(2):123-35. PubMed ID: 12007970
[TBL] [Abstract][Full Text] [Related]
37. Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products.
Sirrs SM; Arthus MF; Bichet DG; Rockman-Greenberg C; LeMoine K; Morel CF; Lachmann R; Lynd LD; Wasim S; West ML; Hollak C
Value Health; 2021 Feb; 24(2):268-273. PubMed ID: 33518033
[TBL] [Abstract][Full Text] [Related]
38. An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe.
Ebbers HC; Langedijk J; Bouvy JC; Hoekman J; Boon WP; de Jong JP; De Bruin ML
Eur J Clin Pharmacol; 2015 Oct; 71(10):1237-44. PubMed ID: 26204969
[TBL] [Abstract][Full Text] [Related]
39. Assessment of genotoxicity of herbal medicinal products: a co-ordinated approach.
Kelber O; Steinhoff B; Kraft K;
Phytomedicine; 2012 Mar; 19(5):472-6. PubMed ID: 22301069
[TBL] [Abstract][Full Text] [Related]
40. Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparison.
Reichert JM; Healy EM
Eur J Pharm Biopharm; 2001 Jan; 51(1):1-7. PubMed ID: 11154897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
